Celon Pharma

Celon Pharma offers information on Salmex drug availability.

Celon Pharma provides a statement on Salmex product availability.

The March 2014 issue of *Terapia Alergologia* published an article by Prof. dr hab. Piotr Kuny comparing therapeutic equivalence of inhalational drugs for asthma and COPD, confirming generics match originals.

The company established a Computer-Aided Drug Design unit to support active-substance development through bio- and chemoinformatics, including virtual screening, binding analysis, ADMET parameter estimation, and QSAR modeling.

Dr Monika Lamparska-Przybysz, head of Celon Pharma’s Innovative Pharmaceutical Products R&D department, presented at the *Managing R&D Projects—How It’s Done in Poland* conference on leading scientific teams in innovative research projects.

Dr hab. Jacek Jaworski, head of the Molecular and Cellular Neurobiology Laboratory at the International Institute of Molecular and Cellular Biology in Warsaw, gave a lecture titled *Kinase mTOR in physiology and neuropathology* at Celon Pharma.

The Medical Chemistry Laboratory received a mass spectrometer paired with a chemical extractor for silica gels, enabling rapid identification of reaction products directly after thin-layer chromatography separation.

Celon Pharma participated in the TEKLA PLUS internship program for researchers (4th edition), hosting trainees in its R&D department from May 20, 2012, to January 20, 2013, with EU Social Fund co-financing.

The August 2014 issue (No. 98) of *Praktyka Lekarska* published a comparison of internal resistance in Salmex generic and Seretide Disk reference inhalers, including statistical analysis of resistance results.

Celon Pharma S.A. is an integrated pharmaceutical company conducting advanced research and producing modern medicines, marketing its own products to improve and extend patients’ lives.

Celon Pharma S.A. secures a positive Notified Body opinion for its pen injector, a key component in developing a semaglutide product. The approval follows earlier bioequivalence results reported in the company’s previous update. The pen injector supports Celon Pharma’s efforts to advance its semaglutide-based treatment pipeline.

Sep 2026Celon PharmaNews article

Celon Pharma reports positive bioequivalence study results for its semaglutide-based drug **Reduzek**, currently in development. The findings validate the product’s equivalence to reference semaglutide formulations, advancing its clinical profile. The study marks a key milestone for Celon Pharma’s pipeline of biosimilar and generic medications.

Aug 2026Celon PharmaNews article

Celon Pharma S.A. partners with Pharmalink Drug Store L.L.C. to commercialize its generic semaglutide product, branded as Reduzek, in Gulf Cooperation Council (GCC) markets. The agreement covers licensing and supply for selected GCC countries, expanding Celon Pharma’s reach in the region’s pharmaceutical market.

Jun 2026Celon PharmaNews article

Celon Pharma S.A. signs a license and supply agreement with Pharmalink Drug Store L.L.C. to commercialize its **Reduzek (semaglutide)** multi-dose pen products in select **Gulf countries**. The deal expands Celon’s market reach in the region for its diabetes and obesity treatment. Terms include licensing and supply obligations under the agreement.

Jun 2026Celon PharmaNews article